Evidence map›Paper›PMID 39465888›Full record

Trial reportInternational journal of toxicology

A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults.

Ross D Peterson, Liana L Guarneiri, Caryn G Adams, Meredith L Wilcox, Anthony J Clark, Nathan P Rudemiller, Kevin C Maki, Carrie-Anne Malinczak

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of toxicology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06012669 nacompletednot on this map

A Randomized, Double-blind, Controlled, Parallel-arm Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function in Healthy Adults

TypeinterventionalSponsorMidwest Center for Metabolic and Cardiovascular ResearchRan2023 to 2023Enrolled66ConditionsImmune HealthArmsHigh dose Human Lactoferrin, Low dose Human Lactoferrin, Active Control Bovine Lactoferrin
NCT07524270 narecruitingnot on this map

Dose-Response of Effera® Supplementation for Women's Health Outcomes

TypeinterventionalSponsorHelaina Inc.Ran2026 to 2026Enrolled160ConditionsWomens Health, Menstrual SymptomsArmsEffera® (human equivalent lactoferrin), Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ross D PetersonHelaina Inc., New York, NY, USA.
Liana L GuarneiriMidwest Biomedical Research, Addison, IL, USA.
Caryn G AdamsMidwest Biomedical Research, Addison, IL, USA.
Meredith L WilcoxMidwest Biomedical Research, Addison, IL, USA.
Anthony J ClarkHelaina Inc., New York, NY, USA.
Nathan P RudemillerImmunologix Laboratories, Tampa, FL, USA.
Kevin C MakiMidwest Biomedical Research, Addison, IL, USA.
Carrie-Anne MalinczakHelaina Inc., New York, NY, USA.ORCID 0000-0003-3377-5921

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant human lactoferrin (rhLF) is of commercial interest for immune support as a food ingredient. The objective was to evaluate the immunogenicity/alloimmunization potential of Helaina rhLF (effera™) from

Indexed as

LactoferrinAdultAnimalsAntibodiesCattleDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedRecombinant ProteinsYoung AdultAntibodiesLactoferrinRecombinant Proteinsalloimmunizationbioactive nutritiondietary supplementsfood ingredient safetyhuman lactoferrinimmunogenicityingredient risk assessmenttolerance

Identifiers

PMID39465888
PMCPMC11731406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.